Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Sosman

Showing results (1-10 of 225) with videos related to

Pageof 23
Sort By:
Journal of the American Society of Nephrology : JASN|October 22, 2003
Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapyJeffrey A Sosman
Expert Review of Anticancer Therapy|March 28, 2008
Improving outcomes in patients with advanced renal cell carcinomaJeffrey A Sosman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Molecular targets in melanoma from angiogenesis to apoptosisJeffrey A Sosman, Igor Puzanov
Expert Review of Vaccines|August 9, 2003
Melacine: an allogeneic melanoma tumor cell lysate vaccineJeffrey A Sosman, Vernon K Sondak
Current Oncology Reports|August 15, 2009
Inside life of melanoma cell signaling, molecular insights, and therapeutic targetsJeffrey A Sosman, Kim A Margolin
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
BRAFV600E-mutant melanoma presenting with cardiac involvementDouglas B Johnson, Jeffrey A Sosman
Seminars in Cancer Biology|March 6, 2004
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: MelacineVernon K Sondak, Jeffrey A Sosman
JAMA Oncology|July 17, 2015
Therapeutic Advances and Treatment Options in Metastatic MelanomaDouglas B Johnson, Jeffrey A Sosman
Cancer Discovery|February 13, 2018
A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?Justin M Balko, Jeffrey A Sosman
Nature Medicine|June 5, 2003
Biological drug duo delivers one-two tumor punchJeffrey A Sosman, James W Mier
Pageof 23

Showing results (1-10 of 225) with videos related to

Sort By:
Pageof 23
Journal of the American Society of Nephrology : JASN|October 22, 2003
Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapyJeffrey A Sosman
Expert Review of Anticancer Therapy|March 28, 2008
Improving outcomes in patients with advanced renal cell carcinomaJeffrey A Sosman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Molecular targets in melanoma from angiogenesis to apoptosisJeffrey A Sosman, Igor Puzanov
Expert Review of Vaccines|August 9, 2003
Melacine: an allogeneic melanoma tumor cell lysate vaccineJeffrey A Sosman, Vernon K Sondak
Current Oncology Reports|August 15, 2009
Inside life of melanoma cell signaling, molecular insights, and therapeutic targetsJeffrey A Sosman, Kim A Margolin
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
BRAFV600E-mutant melanoma presenting with cardiac involvementDouglas B Johnson, Jeffrey A Sosman
Seminars in Cancer Biology|March 6, 2004
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: MelacineVernon K Sondak, Jeffrey A Sosman
JAMA Oncology|July 17, 2015
Therapeutic Advances and Treatment Options in Metastatic MelanomaDouglas B Johnson, Jeffrey A Sosman
Cancer Discovery|February 13, 2018
A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?Justin M Balko, Jeffrey A Sosman
Nature Medicine|June 5, 2003
Biological drug duo delivers one-two tumor punchJeffrey A Sosman, James W Mier
Pageof 23